Peptide education
Acetyl tetrapeptide-5
Eyeseryl
Acetyl tetrapeptide-5 is a synthetic peptide made of four amino-acid building blocks. It is used in eye-area creams and serums. The supplier Lipotec uses the name Eyeseryl for a solution containing the peptide.
A supplier reported changes in the appearance of under-eye puffiness in 20 volunteers using a cream. The report did not describe a comparator or an independent blinded assessment.
Overview
Quick answer
The supplier describes a small volunteer panel, not a peer-reviewed controlled trial. The reported concentration wording does not clearly distinguish the peptide from the supplier's solution.
What has been observed in people?
A supplier described 20 women using a cream for 60 days and reported improvement in a visual puffiness score. The document did not describe a control group.
Does it remove under-eye bags?
The panel is too limited to establish an ingredient-specific effect. Under-eye bags can have different causes, and a cosmetic cream cannot be assumed to address all of them.
What about eye safety?
The supplier mentioned an in vitro ocular irritation test but provided limited methods. Products intended for skin around the eye are not automatically suitable for application inside the eye.
Evidence
Evidence snapshot
A dermatologist assessed photographs and gave a visual puffiness score.
The supplier report does not identify a placebo or vehicle control.
Experiments included the peptide on its own and within peptide mixtures.
The supplier mentioned an in vitro ocular irritation test without a full clinical safety assessment.
Claims
Common claims vs evidence
| Claim | Human evidence | Mechanistic evidence | Verdict |
|---|---|---|---|
| The peptide reduces under-eye bags. | A supplier reported improved visual scores in a small group using a cream. Its document did not describe a comparator. | Laboratory enzyme and fibroblast experiments do not measure under-eye appearance. | The supplier observation does not establish the peptide's independent effect. |
| A laboratory enzyme result proves improved circulation around the eyes. | The supplier panel did not measure a peptide-specific change in blood flow. | A separate laboratory study tested enzyme activity and peptide mixtures in cells. | Enzyme assays cannot establish an effect in living eye-area skin. |
Bottom line
Main takeaway
This ingredient appears in eye-area cosmetics, but the human evidence for puffiness is preliminary.
Distinguish a supplier's ingredient solution from the concentration and ingredients of a finished cream.
Separate supplier-reported observations, enzyme assays, and clinical studies with a suitable comparator.
Identity
What it is
Acetyl tetrapeptide-5 is used in skin-care products designed for the eye area. The supplier describes its ingredient solution for use in creams, gels, and serums.
A supplier solution contains the peptide together with other ingredients; the concentration of that solution in a formula is not the same thing as the final concentration of the peptide.
Research
Research evidence
The supplier's technical document describes a small volunteer panel. Its reported visual changes need a controlled comparison to establish whether the peptide contributes to the result.
| Study / evidence area | Population | Design | Product context | Main outcome | Limitations | Weight |
|---|---|---|---|---|---|---|
| Supplier-reported cream panel | 20 female volunteers | Repeated photographs and visual puffiness scoring over 60 days | Eye-area cream described as containing Eyeseryl; the complete cream formula was not provided | The supplier reported improvements in visual scores in many volunteers. | No control group or independent blinded assessment is described. The amount wording does not clearly distinguish peptide from ingredient solution. | Preliminary supplier-reported human observation |
Use context
Reported use context
The supplier described an eye-area cream used in a volunteer panel.
Study and label context
The supplier described a cream containing 0.01% Eyeseryl, applied twice daily for 60 days.
The supplier's separate solution specification lists 0.1% peptide, but the report does not clarify whether the cream's 0.01% refers to active peptide or solution. It does not describe a control group.Cautions
Safety and unknowns
- The supplier mentioned a laboratory ocular irritation test, but its brief description does not establish the safety of every finished product.
- Skin irritation or allergy can arise from the peptide or another ingredient in a finished formulation.
- Products designed for skin around the eyes should not be assumed suitable for use inside the eye.
Product quality
Product identity and quality
Supplier solution concentration and active-peptide concentration are different measurements.
Ingredient identity
A supplier's trade name can refer to a solution rather than pure peptide.
Concentration basis
The proportion of a diluted solution does not identify the final peptide strength by itself.
Intended use
A product for surrounding skin is not automatically an eye preparation.
Mechanism
How it is proposed to work
Researchers have tested the peptide in an enzyme assay and in combinations applied to cultured skin cells. These laboratory observations do not show how it changes under-eye appearance in people.
The cell study combined acetyl tetrapeptide-5 with other peptides when measuring responses to oxidative stress in fibroblasts.
Details
Technical details
Sources
References
- 1.
Lipotec ingredient supplier document. Eyeseryl ingredient technical information and volunteer panel
A Lipotec technical document reproduced in a product dossier describes a 20-woman panel and a 0.1% peptide supplier solution. It does not clearly establish whether the cream's stated 0.01% refers to peptide or solution.
- 2.
doi:10.1159/000514496 PMID:33849044
Laboratory enzyme and fibroblast experiments, including combinations of several peptides.
- 3.
FDA. Is It a Cosmetic, a Drug, or Both? (Or Is It Soap?)
A product's intended use affects its US regulatory classification.